Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

337
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
337
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

675
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
675
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

333
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
333
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

1.1K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.1K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

720
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
720
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

350
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
350

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathomechanism of Fever-Induced Liver Failure in NBAS Deficiency and Treatment Effect of NAC-Observations In Vitro and In Vivo.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Development of multicenter consensus care plans for immunosuppression after pediatric liver transplant: Reducing variability, creating comparative efficacy opportunities.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Material economic hardships are associated with second-year hospitalizations after pediatric liver transplantation: Results from the SOCIAL-Tx study.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Meeting Report: The 2025 Annual Meeting of the Society of Pediatric Liver Transplantation.

Transplantation·2026
Same author

Identifying patient-centered outcomes in progressive familial intrahepatic cholestasis: Results from IMPACT.

Journal of pediatric gastroenterology and nutrition·2026
Same author

Strategies and Innovations Defining the Next Era in Pediatric Liver Transplantation: Unifying Concepts to Tackle a Rare Disease.

Pediatric transplantation·2026

Related Experiment Video

Updated: Mar 31, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K

Tacrolimus interaction with dexmedetomidine--a case report.

Sarah R Stiehl1, James E Squires2, John C Bucuvalas2

  • 1Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Pediatric Transplantation
|October 24, 2015
PubMed
Summary

Dexmedetomidine may increase tacrolimus levels in pediatric liver transplant patients. Careful monitoring of tacrolimus is crucial during dexmedetomidine infusions to prevent toxicity.

Keywords:
dexmedetomidinepediatric liver transplantationtacrolimustherapeutic drug monitoring

More Related Videos

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.2K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.9K

Related Experiment Videos

Last Updated: Mar 31, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.2K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.9K

Area of Science:

  • Pharmacology
  • Transplantation Medicine
  • Pediatric Critical Care

Background:

  • Tacrolimus, an immunosuppressant, is crucial post-liver transplantation.
  • Inhibition of CYP-450 3A4 enzyme is known to increase tacrolimus levels.
  • Dexmedetomidine's potential interaction with tacrolimus metabolism was previously undocumented.

Observation:

  • A case study involving an 8-month-old pediatric liver transplant recipient was reviewed.
  • The patient received a continuous infusion of dexmedetomidine for sedation.
  • Serum tacrolimus trough levels were monitored before, during, and after dexmedetomidine administration.

Findings:

  • Initiation of dexmedetomidine resulted in a 4-fold increase in serum tacrolimus levels within 21 hours.
  • Tacrolimus doses were reduced by 75% to maintain therapeutic levels during dexmedetomidine infusion.
  • Tacrolimus levels returned to below goal range within 30-40 hours of discontinuing dexmedetomidine.

Implications:

  • Dexmedetomidine is a CYP 3A4 inhibitor, potentially interfering with tacrolimus metabolism.
  • Close monitoring of tacrolimus levels is recommended in pediatric patients receiving dexmedetomidine.
  • This interaction highlights the need for vigilant drug management in transplant recipients.